NASDAQ:GTXI - GTX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.64
▲ +0.89 (15.48%)
Get New GTX Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GTXI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GTXI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for GTX in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $6.64.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in GTX. This rating has held steady since August 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/21/2018Stifel NicolausDowngradeBuy ➝ HoldN/A
i
9/21/2018Robert W. BairdDowngradeOutperform ➝ Neutral$17.00N/A
i
3/15/2018Robert W. BairdReiterated RatingBuy$30.00Low
i
3/6/2018Robert W. BairdReiterated RatingBuy$20.00Low
i
3/5/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$16.00 ➝ $45.00High
i
11/21/2017Robert W. BairdInitiated CoverageOutperform ➝ Outperform$17.00N/A
i
11/9/2017Stifel NicolausInitiated CoverageBuy ➝ BuyN/A
i
9/9/2016Jefferies Financial GroupReiterated RatingHold$1.00N/A
i
8/10/2016Jefferies Financial GroupLower Price TargetHold$0.75 ➝ $0.50N/A
i
(Data available from 4/22/2016 forward)
GTX logo
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
Read More

Today's Range

Now: $6.64
$5.83
$6.77

50 Day Range

MA: $4.77
$1.20
$7.20

52 Week Range

Now: $6.64
$0.74
$25.60

Volume

1,910,888 shs

Average Volume

390,540 shs

Market Capitalization

$159.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.22

Frequently Asked Questions

What sell-side analysts currently cover shares of GTX?

The following sell-side analysts have issued stock ratings on GTX in the last twelve months:
View the latest analyst ratings for GTXI.

What is the current price target for GTX?

0 Wall Street analysts have set twelve-month price targets for GTX in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for GTX in the next year.
View the latest price targets for GTXI.

What is the current consensus analyst rating for GTX?

GTX currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GTXI.

What other companies compete with GTX?

How do I contact GTX's investor relations team?

GTX's physical mailing address is 17 W Pontotoc Ave. Suite 100, MEMPHIS TN, 38103. The biopharmaceutical company's listed phone number is 901-523-9700 and its investor relations email address is [email protected] The official website for GTX is www.gtxinc.com.